Trial Profile
A Dose-Escalating, Single-Blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Elarekibep (Primary) ; Elarekibep (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors AstraZeneca; Pieris Pharmaceuticals
- 22 Dec 2020 Status changed from recruiting to completed.
- 12 Aug 2020 Planned number of patients changed from 75 to 84.
- 12 Aug 2020 Planned End Date changed from 1 Apr 2020 to 5 Dec 2020.